Quantinno Capital Management LP Raises Stock Position in Biogen Inc. $BIIB

Quantinno Capital Management LP lifted its holdings in Biogen Inc. (NASDAQ:BIIB) by 18.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 116,374 shares of the biotechnology company’s stock after buying an additional 18,041 shares during the period. Quantinno Capital Management LP’s holdings in Biogen were worth $21,335,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Reflection Asset Management purchased a new position in Biogen in the fourth quarter worth about $25,000. WPG Advisers LLC raised its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the period. First Horizon Corp purchased a new stake in Biogen during the fourth quarter valued at approximately $30,000. Root Financial Partners LLC lifted its stake in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. bought a new stake in shares of Biogen in the 4th quarter valued at approximately $34,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Citigroup boosted their target price on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Guggenheim lifted their price objective on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. The Goldman Sachs Group boosted their price objective on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $223.36.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

Biogen Trading Down 2.4%

Shares of NASDAQ BIIB opened at $202.95 on Friday. Biogen Inc. has a fifty-two week low of $124.56 and a fifty-two week high of $219.72. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.41 and a current ratio of 1.87. The company has a market cap of $29.99 billion, a price-to-earnings ratio of 35.92, a PEG ratio of 6.28 and a beta of 0.16. The business’s 50 day moving average price is $201.23 and its 200-day moving average price is $190.60.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts expect that Biogen Inc. will post 12.65 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.